Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un nuevo compuesto químico contra el cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20171123001
Publicado:
24/04/2018
Caducidad:
25/04/2019
Resumen:
Una oficina francesa de transferencia de tecnología ofrece un nuevo compuesto químico con propiedades de inhibición vascular y antiproliferativas validadas in vitro e in vivo. Se trata de una nueva clase de agentes químicos con una fuerte actividad anticancerígena para el tratamiento de tumores sólidos y, en particular, en el colon, pulmones, ovarios y útero. El compuesto ha demostrado una potencia anticancerígena muy eficiente en modelos in vitro utilizando 24 líneas de células cancerígenas, algunas de ellas resistentes a la quimioterapia. In vivo, el compuesto ha demostrado una reducción del volumen del tumor de hasta un 80-95% en modelos murinos de pulmón y colon sin efectos secundarios importantes. La oficina busca socios tecnológicos con el fin de establecer acuerdos de licencia, cooperación técnica o investigación.

Details

Tittle:
A French Technology Transfer Office offers a novel anti-cancer chemical compound
Summary:
A French Technology Transfer Office (TTO) offers a novel chemical compound with anti-proliferative and vascular inhibition properties validated in vitro and in vivo. It is a new class of chemical agents with a strong anti-cancer activity for the treatment of solid tumors, in particular in the colon, lung, ovaries and uterus.
The French TTO is looking for technological partners for a license agreement, technical cooperation agreement or a research cooperation agreement.
Description:
The French Technology Transfer Office (TTO) is acting on behalf of an established public laboratory of a university of the Paris region.
The present offer proposes a novel chemical compound with non-proliferative and vascular inhibition properties validated in vitro and in vivo.

It is a class of chemical agents targeting tubulin polymerization with a high hydrophilic structure and a strong anti-cancer activity.
This compound has shown highly efficient anti-cancer potency in vitro models using 24 cancer cell lines (some of them being resistant to chemotherapies).

In vivo, after intra-peritoneal injection, this compound has shown a tumor volume reduction of 80-95% on lung and colon murine tumors with no major identified side effects.
After intra-peritoneal injection, the pharmacokinetic profile in mice is good with a half-life of 91mn and a bioavailability of 47%.

There is a need for new anticancer agents associated with increased response rates and with limited and manageable toxicity.

This treats solid tumors, in particular in the lungs which is the most common cause of cancer-related death in men and the second most common in women; in the colon which is the third most common type of cancer for all groups; in the ovaries which is the seventh-most common cancer for woman; and also in the uterus.

Keywords :
Anti-proliferative, anti-vascular, anti-cancer, treatment, solid tumors, cancer, lung cancer, colon cancer, ovaries cancer, uterus cancer, tubulin polymerization, Tumor Therapy

The partner sought could be a university, a SME or a large company interested in a license agreement or a research cooperation agreement or a technical cooperation agreement.
The French TTO is able to provide technical and legal assistance to facilitate the eventual partnership. In case of business potential, the prototype can be partially funded by the TTO.
Advantages and Innovations:
The advantages of this technology are:
- water soluble
- stable and easy to synthetize
- high efficiency in a powerful in vitro colon 26 cell lines
- better efficacy than the anti-vascular comparator combretastatin CA4.
Stage of Development:
Available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patent Cooperation Treaty (PCT) application
Publication date : Jul 23, 2015

Partner sought

Type and Role of Partner Sought:
The partner sought could be a large corporate, medium-sized company or startup operating in pharmaceutical, drug design or biotechnology development.
These companies are focused in order to set up a licensing agreement, or a technical cooperation agreement in case of further needed development to meet industrial and clinical challenges.
The partner sought could be also a university in order to launch a research cooperation agreement with the French laboratory.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002001 Bioquímica / biofísica
06001003 Citología, cancerología, oncología
06002008 Microbiología